NASDAQ:ELGX - Nasdaq -
0.22
-0.07 (-23.88%)
The current stock price of ELGX is 0.22 null. In the past month the price decreased by -77.55%. In the past year, price decreased by -96.71%.
Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis.
Endologix Inc
2 MUSICK
IRVINE CA 92618
CEO: John Onopchenko
Phone: 949-595-7200
The current stock price of ELGX is 0.22 null. The price decreased by -23.88% in the last trading session.
The exchange symbol of Endologix Inc is ELGX and it is listed on the Nasdaq exchange.
ELGX stock is listed on the Nasdaq exchange.
Endologix Inc (ELGX) has a market capitalization of 4.22M null. This makes ELGX a Nano Cap stock.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ELGX does not pay a dividend.
Endologix Inc (ELGX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.13).
ChartMill assigns a fundamental rating of 2 / 10 to ELGX. ELGX may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months ELGX reported a non-GAAP Earnings per Share(EPS) of -2.13. The EPS increased by 67.33% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | -44.65% | ||
ROA | -20.26% | ||
ROE | N/A | ||
Debt/Equity | 0.29 |
ChartMill assigns a Buy % Consensus number of 50% to ELGX. The Buy consensus is the average rating of analysts ratings from 4 analysts.